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Abstract  
Objective: Drug malabsorption is one of the potential troubles after bariatric surgery. Evidence 
for diminished Levothyroxine (L-T4) absorption has been reported in patients after bariatric 
surgery. 
Methods: This study reports 17 cases of hypothyroid patients [who were well replaced with 
thyroxine tablets (for > 1 year) to euthyroid thyrotropin (TSH) levels before surgery (13 Roux-
en-Y gastric bypass (RYGB); 4 biliary pancreatic diversions (BPD)]. From 3 to 8 months after 
surgery, these patients had elevated TSH levels. Patients were then switched from oral tablets to 
a liquid L-T4 formulation (with the same dosage, 30 minutes before breakfast).  
Results: Two-three months after the switch, TSH was significantly reduced both in patients 
treated with RYGB, as in those treated with BPD, while FT4 and FT3 levels were not 
significantly changed (RYGB group, TSH µIU/mL: 7.58 ± 3.07 vs 3.808 ± 1.83, P < 0.001; BPD 
group, TSH µIU/mL: 8.82 ± 2.76 vs 3.12 ± 1.33, P < 0.01). 
Conclusions: These results first show that liquid L-T4 could prevent the problem of 
malabsorption in patients with BPD, and confirm those of previous studies in patients submitted 
to RYGB, suggesting that the L-T4 oral liquid formulation could circumvent malabsorption after 
bariatric surgery. 
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Introduction 
In the past decades, demand for bariatric surgery has globally increased, and about 101 000-180 
000 surgeries are performed annually in the US alone [1-4].  
Surgical procedures include different types of operations: a- purely restrictive (gastric banding, 
gastroplasty); b- restrictive with limitation of digestive capacity (sleeve gastrectomy); c- 
restrictive/malabsorptive (gastric bypass); d- purely malabsorptive (biliopancreatic diversion, 
jejunoileal bypass). Malabsorptive procedures can lead to nutritional deficiencies, [5] or drug 
malabsorption [6].  
People with severe obesity receiving bariatric surgery often have multiple medical comorbidities 
requiring multidrug treatments. After diversionary procedures drug malabsorption is a potential 
concern. In fact nearly all oral agents are absorbed mainly in the small intestine, which is 
bypassed in several bariatric procedures. Other factors that impair drug absorption are: 
diminished opportunity for mucosal exposure, and changes in drug solubility and dissolution 
resulting from alterations in intestinal pH [6]. The most consistent evidence for diminished 
absorption has been found for cyclosporine, phenytoin, rifampin and thyroxine [7].  
The prevalence of hypothyroidism in patients with morbid obesity range fro 12 to 25% [8, 9]. 
Moreover, in obese males, insulin resistance is significantly related with thyroid function 
impairment [10].  
Levothyroxine (L-T4) is the gold standard and effective replacement therapy for patients with 
hypothyroidism for autoimmune thyroiditis or after radioablative therapies, or suppressive 
therapy after surgical removal of thyroid cancer [11-13].  
To obtain an effective therapy, some requisites are necessary, as L-T4 products are of optimal 
quality, [14] patients’ compliance, [15] dissolution of the hormone in the stomach, [16] adequate 
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absorption in the intestines, [17, 18] and normal metabolism [19]. Several diseases and drugs 
affect the absorption and metabolism of L-T4 [20]. Gastritis causes L-T4 malabsorption, by 
altering the gastric juice pH, thereby affecting L-T4 dissolution [21-23].  
Evidence for diminished L-T4 absorption has been reported in patients after bariatric surgery 
[24, 25].  
Recently four cases of hypothyroid patients who were well replaced with thyroxine tablets to 
euthyroid thyrotropin (TSH) levels prior to Roux-en-Y gastric bypass (RYGB) surgery, and 
developed elevated TSH levels after the surgery, have been reported [26]. In these patients TSH 
responded reversibly to switching from L-T4 treatment with oral tablets to a liquid formulation. 
Here, we report our experience with the use of liquid L-T4 in patients with bariatric surgery who 
had developed elevated TSH levels after the surgery. 
 
Methods 
We have evaluated 17 out-patients with morbid obesity, recruited from the end of 2013 to first 
months of 2015 (10 females, 7 males; age 31-59 years), who were diagnosed with 
hypothyroidism (11 affected by autoimmune thyroiditis, and 6 treated with total thyroidectomy 
for multinodular goiter) before the bariatric surgery, and were well replaced with thyroxine 
tablets (for >1 year) to euthyroid TSH, free thyroxine (FT4) and free triiodothyronine (FT3) 
levels. Thirteen patients were treated with RYGB, [27] while 4 with biliary pancreatic diversions 
(BPD) [28].  
The RYGB group included 9 women and 4 men, mean age of 45 ± 9 years; body mass index 
(BMI) (before surgery) in this group was ≥ 40 kg/m2 (mean, 42.9 ± 3.5 kg/m2). The 
hypothyroidism in this group was due in 9 cases to autoimmune thyroiditis, and in 4 to total 
thyroidectomy for multinodular goiter. 
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The BPD group included 1 woman and 3 men, mean age of 42 ± 7 years; BMI (before surgery) 
in this group was ≥ 40 kg/m2 (mean, 44.1 ± 4.4 kg/m2). The hypothyroidism in this group was 
due in 2 cases to autoimmune thyroiditis, and in 2 to total thyroidectomy for multinodular goiter. 
From 3 to 8 months after surgery, these patients had elevated TSH levels.  
We decided to treat these patients with oral liquid L-T4. Patients were switched from oral tablets 
to a liquid formulation of L-T4 (Tirosint® fiala monouso, IBSA Farmaceutici Italia) (with the 
same dosage, 30 minutes before breakfast). Two-three months after the switch, circulating TSH, 
FT4 and FT3 were re-evaluated. Clinical data and medication information were collected before 
recruitment from medical records. Patients with other possible causes of altered L-T4 absorption 
(such as atrophic gastritis, and use of medications associated with impaired L-T4 absorption), 
were not evaluated. 
All patients signed an informed consent. The study was approved by the Ethical Committee. 
Serum FT4 (normal range, 0.7 - 1.7 ng/dL), FT3 (normal range, 2.7 - 4.7 pg/ml), and serum TSH 
(normal range, 0.4 - 4 µIU/mL) were determined in all samples by electrochemiluminescence 
immunoassay (Roche Corporation, Indianapolis, IN, USA). The concentration of each hormone 
at baseline, and after the switch, was calculated as a mean of the two samples collected before 
the L-T4 dose.  
Data analysis  
Values are given as mean ± SD for normally distributed variables, otherwise as median and 
[interquartile range]. Mean group values were compared by using one-way analysis of variance 
(ANOVA) for normally distributed variables (age and BMI). Post-hoc comparisons on normally 
distributed variables were carried out using the Bonferroni-Dunn test. Proportions were 
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compared by the χ2 test. Simple regression was used to evaluate the correlation among changes 
of TSH (after the switch - baseline), vs changes of FT4, or FT3.  
 
Results 
After bariatric surgery (at the time of TSH re-evaluation, 3 to 8 months after surgery) in the 
RYGB group BMI was reduced from 42.9 ± 3.5 kg/m2 to 37.9 ± 2.7 kg/m2 (P < 0.01), while in 
the BPD group BMI was reduced from 44.1 ± 4.4 kg/m2 to 38.6 ± 3.7 kg/m2 (P < 0.01). 
Although the reduction of body weight, with the same L-T4 dosage (mean 192 ± 32 µg/day) in 
tablets, 30 minutes before breakfast, after bariatric surgery TSH was increased in both groups 
(Table 1), while FT4 and FT3 levels were not significantly changed. The only symptom 
observed in patients with high TSH was fatigue in 11/17 (65%) of patients. Then patients were 
switched from oral tablets to a liquid formulation of L-T4 (Tirosint® fiala monouso, IBSA 
Farmaceutici Italia) (with the same dosage, 30 minutes before breakfast). Two-three months after 
the switch, when circulating TSH, FT4 and FT3 were re-evaluated, in the RYGB BMI was 
reduced from 37.9 ± 2.7 kg/m2 to 36.3 ± 2.5 kg/m2 (P < 0.01), while in the BPD group BMI was 
reduced from 38.6 ± 3.7 kg/m2 to 37.9 ± 3.4 kg/m2 (P > 0.05). 
After the switch from oral tablets to a liquid formulation of L-T4, circulating TSH levels were 
significantly reduced in both groups, while FT4 and FT3 levels were not significantly changed 
(RYGB group, TSH µIU/mL: 7.58 ± 3.07 vs 3.808 ± 1.83, P < 0.001; BPD group, TSH µIU/mL: 
8.82 ± 2.76 vs 3.12 ± 1.33, P < 0.01) (Fig. 1). 
The comparison of TSH values before surgery, 3 to 8 months after surgery, and 2-3 months after 
the switch are shown in Fig. 2, and data show that the TSH values after the switch are higher, 
even if not significantly (P = 0.064), with respect to the TSH values before surgery. 
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A negative correlation between decrease of TSH (after the switch - baseline), vs the increase of 
FT4 (after the switch - baseline) was observed by simple regression (r = 0.754, P = 0.007) (Fig. 
3). While no significant association was observed between changes of TSH (after the switch - 
baseline) and changes of FT3 (after the switch - baseline). 
There was no significant difference between gender in changes of TSH values after surgery, or in 
the response to the switch to the liquid L-T4 formulation.  
No patient before and after bariatric surgery, or after the switch had euthyroid sick syndrome 
[29].  
Albumin levels were in the normal range (3.5 to 5.5 g/dL) in all patients before and after 
bariatric surgery, or after the switch. 
 
Discussion  
The abovementioned data suggest that the L-T4 oral liquid formulation could avoid the problem 
of the malabsorption after bariatric surgery. The obtained results first show that liquid L-T4 
could prevent the problem of the malabsorption in patients with BPD, and confirm those 
obtained in a previous study in patients submitted to RYGB. The serum TSH levels in our 
patients (according to the selection criteria) was increased after bypass surgery, suggesting a 
malabsorption of L-T4, [24-26] in agreement with Azizi et al., Bevan et al. and Pirola et al. 
RYGB reduces the size of the stomach to a small pouch – about the size of an egg. It does this by 
stapling off a section of it. This reduces the amount of food patients can take in at meals. This 
pouch is then attached directly to the small intestine, by-passing most of the rest of the stomach 
and the upper part of the small intestine, and reducing the amount of fat and calories that are 
absorbed from the foods [30]. A recent review demonstrated that RYGB is associated with 
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diminished absorption of lypophilic drugs such as cyclosporine, phenytoin, rifampin and 
thyroxine [7].  
BPD is a bariatric surgery for patients with severe obesity. The primary mechanism of weight 
loss with the BPD is malabsorption. BPD removes approximately 3/4 of the stomach to produce 
both restriction of food intake and reduction of acid output. Leaving enough upper stomach is 
important to maintain proper nutrition. The small intestine is then divided with one end attached 
to the stomach pouch to create what is called an “alimentary limb.” All the food moves through 
this segment, however, not much is absorbed. The bile and pancreatic juices move through the 
“biliopancreatic limb,” which is connected to the side of the intestine close to the end. This 
supplies digestive juice in the section of the intestine now called the “common limb.” The 
surgeon varies the length of the common limb to regulate the amount of absorption of protein, fat 
and fat-soluble vitamins [31, 32]. A recent review demonstrated that also BPD is associated with 
diminished absorption of lypophilic drugs and thyroxine [31].  
The mechanisms by which liquid L-T4 circumvent malabsorption in bariatric surgery remain to 
be studied. It has been suggested that absorption of thyroxine is greater with oral liquid 
formulations in patients after bariatric surgery [26]. In fact, normal gastric acid secretion is 
necessary for effective absorption of L-T4 [18] by dissolution of tablets, and drug dissolution 
and solubility may be altered by restrictive procedures that increase gastric pH in the newly 
created stomach pouch; this may occur in gastric bypass [7]. Since it has been shown that the 
liquid formulation of L-T4 is extremely effective to circumvent the problem of incomplete 
absorption of L-T4 caused by proton pump inhibitor-induced, [33] this formulation could also 
circumvent the pH alteration resulting from gastric bypass [34]. 
Furthermore the presence of alcohol in the L-T4 liquid formulation could also play a key role in 
thyroxine absorption. Indeed, oral mucosal is highly vascularised, and drugs that are absorbed 
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through the oral mucosal directly enter the systemic circulation, bypassing the gastrointestinal 
tract [35]. Further studies are needed to clarify these intriguing points. 
The comparison of TSH values before surgery, after surgery, and 2-3 months after the switch 
show that the TSH values after the switch are higher (near to the statistical significance, P = 
0.064), with respect to the TSH values before surgery. These results suggest that in patients with 
bariatric surgery a slight malabsorption persits even when the liquid L-T4 formulation is given. 
However, there was no significant difference in the decrease of TSH in RYGB group vs the BPD 
group, nor in females vs males. 
In conclusion, the abovementioned data suggest that the L-T4 oral liquid formulation could 
circumvent L-T4 malabsorption both in patients submitted to BPD, as in those submitted to 
RYGB; further studies are needed to enlarge the number of participants and to clarify the 
implicated mechanisms . 
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Figure Legends 
 
Figure 1. Change of TSH levels in RYGB group (A), or in the BPD group (B), after surgery, and 
2-3 months after the switch from oral tablets to a liquid formulation of Levothyroxine (with the 
same dosage, 30 minutes before breakfast). There was no significant difference in the decrease 
of TSH in RYGB group, vs the BPD group. 
Figure 2. Comparison of TSH values before surgery, 3 to 8 months after surgery, and 2-3 
months after the switch in all bariatric patients, are shown. The TSH values (box-plot) after the 
switch are higher, even if not significantly (P = 0.064), with respect to the TSH values before 
surgery. 
Figure 3. A negative correlation between decrease of TSH (after the switch - baseline) (TSH 
final – TSH basal), vs the increase of FT4 (after the switch - baseline) (FT4 final – FT4 basal), 
was observed by simple regression (r = 0.754, P = 0.007). 
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Table 1. TSH, FT4, FT3 levels before and after bariatric surgery. 
 RYGB 
(before surgery) 
RYGB 
(after surgery) 
P value 
(by ANOVA) 
TSH	   2.21 ± 0.91 7.58 ± 3.07 < 0.001 
FT4	   1.27 ± 0.31	   1.18 ± 0.37	   ns	  
FT3	   3.12 ± 0.91	   2.98 ± 0.98	   ns	  
 
BPD 
(before surgery) 
BPD 
(after surgery) 
 
TSH	   2.65 ± 0.86 8.82 ± 2.76 0.005 
FT4	   1.31 ± 0.28	   1.20 ± 0.36	   ns	  
FT3	   2.99 ± 0.92	   2.87 ± 0.96	   ns	  
Roux-en-Y gastric bypass (RYGB); Biliary pancreatic diversions (BPD). Serum 
TSH, normal range 0.4 – 4 µIU/mL; serum FT4, normal range 0.7 – 1.7 ng/dL; 
serum FT3, normal range 2.7 – 4.7 pg/mL. 
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